Möchten Sie immer auf dem neuesten Stand bleiben?

ACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those...

Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine...

Emerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries  Retrospective contact...

NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions  Point of care in office...

Heads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1]  Offers enhanced 3D visualization with high-definition resolution, image depth,...

Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study  Analyses show that Ultibro Breezhaler lowered...

New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.  Study highlights importance of improving treatment...

Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine  Erelzi is approved for all indications included in the reference product's...

13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business Interactive program brings...

Im Zentrum des 13. International Biotechnology Leadership Camp steht das Potenzial neuer Technologien, die biomedizinische Forschung und die Pharmabranche grundlegend zu verändern Das interaktive...